The facility has been designed by Foster + Partners and is devoted to reimagining and redefining cancer treatment whilst enhancing overall human health and global health policy.
The transaction is part of The Oxford Science Park’s ongoing investment programme, providing the support infrastructure for growing companies as they address global health and environmental challenges.
New occupiers, CyanoCapture and Ochre Bio, are joining MiroBio, MoA Technology and Oxford Nanopore Technologies, who are expanding their footprint on the Park, as well as Circassia, which is relocating from another building.
The company, which initially occupied c7,800 sq ft in the Schrödinger Building is increasing capacity for its technology teams by expanding to 21,000 sq ft of facilities.
The machine learning immunotherapy discovery company joins a group of thriving companies which use artificial intelligence techniques in their research.
The studies will allow the company to assess the ability of its next-generation vaccine to boost the immune response against current and potential future strains of COVID-19.
Japan Airlines flight (JAL #515) from Tokyo to Sapporo completed the flight on 17 June using sustainable aviation fuel (SAF) from woody biomass residue feedstock produced by the company’s proprietary technology.
The 745 sq ft molecular diagnostics research and quality control lab will support its customers in developing improved molecular diagnostics for COVID-19 and other pathogens.
The c.28,000 sq ft building, let in its entirety to the Oxford Science Innovation (OSI), was acquired from MRP, the property arm of construction firm McAleer & Rushe.
Its 14.75 acres of development land has the capacity for 420,000 sq ft to support the growth of existing occupiers and enable new companies to join the thriving campus.
The move from the Oxford BioEscalator to one of the UK’s largest biomedical innovation centres is in preparation for its future growth and ambition to transform cancer care.